Introduction {#sec1-1}
============

*Staphylococcus aureus* comprises Gram-positive aerobic or facultatively anaerobic cocci in clusters, occurring as normal flora of the skin, axilla, and anterior nares of man and animals. However, *S. aureus* is implicated in diseases of the skin and soft tissues, pneumonia, bloodstream infections, osteomyelitis, and endocarditis, as well as toxin-mediated syndromes such as toxic shock and food poisoning \[[@ref1], [@ref2]\]. The organism has developed resistance to a wide range of antimicrobial drugs, which complicates the treatment of these infections. *S. aureus* is also a common cause of hospital and community acquired infections. Mortality associated with severe *S. aureus* infections in the developing world far exceeds that in developed countries \[[@ref3]\]. Recent studies have identified *S. aureus* as the main etiological agent of many infections in sub-Saharan Africa \[[@ref4], [@ref5]\], and a number of investigators have reported that *S. aureus* is among the most frequently encountered bacterial species in microbiology laboratories in Nigeria \[[@ref6], [@ref7]\]. Molecular data on this pathogen in Nigeria is however very limited.

As early as 1950, vancomycin, the first glycopeptide antibiotic to be discovered \[[@ref8]\], was the drug of choice for therapy of infections caused by methicillin (meticillin)-resistant *S. aureus* (MRSA), but increase in vancomycin use has led to the emergence of two types of glycopeptide-resistant *S. aureus.* The first one, designated vancomycin intermediate-resistant *S. aureus* (VISA), is associated with a thickened and poorly cross-linked cell wall, resulting in accumulation of acyl-D-alanyl-D-alanine (X-D-Ala-D-Ala) targets at the periphery of the cell that sequester glycopeptides \[[@ref9]\]. The second type, vancomycin-resistant *S. aureus* (VRSA), is due to acquisition of *vanA* operon from *Enterococcus* spp. \[[@ref10], [@ref11]\], carried by transposon *Tn1546*, resulting in high-level resistance \[[@ref12]\].

Since the discovery of vancomycin-resistant *Enterococcus* (VRE) in the late 1980s \[[@ref13]\], concern regarding the emergence of vancomycin resistance in isolates of MRSA by transfer of plasmids was always present. The first reports of reduced susceptibility of *S. aureus* to vancomycin were in 1997 \[[@ref14], [@ref15]\]. Since then, the threat of vancomycin resistance in *S. aureus* has been the topic of intense research and discussion. Although vancomycin resistance in *S. aureus* remains extremely rare, there is widespread concern that VRSA poses by far the greatest risk to patients due to the organism\'s virulent nature. Also, this virulent nature of *S. aureus* coupled with the limited options of MRSA infections treatment makes the emergence of VRSA a significant public health threat. Furthermore, there is the equally alarming threat of the risk of transmission of these organisms between patients.

In 2002, a fully vancomycin-resistant strain of MRSA emerged and was first reported from the United States of America \[[@ref12], [@ref16]\]. As expected, the vancomycin resistance gene cluster *vanA* has been acquired by these strains from vancomycin-resistant enterococci. Eleven cases of VRSA infection in the US have since been reported, with the majority from Michigan area (where seven cases were recovered), Pennsylvania, New York, and Delaware \[[@ref12], [@ref17]\] and from outside the US in India \[[@ref18], [@ref19]\] and Iran \[[@ref20]\]. The responsible mechanism for vancomycin resistance in these strains has been found to be the acquisition of resistance plasmids carrying *vanA* or *vanB* operon. Except for the few \[[@ref18]\] out of several reports, the genetic mechanisms of VRSA isolates from Iran and India \[[@ref21]\] are not yet known. The first VRSA isolate in Europe was reported from Portugal in 2013 \[[@ref25]\], and this isolate carried *mecA* and *vanA* genes probably acquired from VRE that coinfected the patient from whom the isolate was recovered.

Vancomycin resistance has been demonstrated to be inducible *in vitro* for many of the VRSA strains \[[@ref26]\]. Also, in a majority of the cases, VRE strains have been isolated along with the VRSA strains from the same patients. This goes in favor of the popular theory that the *Tn1546* plasmid which carries the *vanA* gene cluster found in such strains is acquired from VRE \[[@ref18], [@ref27]\]. In Nigeria, previous studies on vancomycin testing of clinical *S. aureus* isolates have reported full susceptibility with the disk diffusion, broth dilution, or automated Vitek-2 susceptibility test system \[[@ref28]\]. Few studies \[[@ref32]\], however, have reported clinical VISA isolates in some parts of the country, but only two studies \[[@ref35], [@ref36]\] have reported clinical VRSA strains using vancomycin agar screen, broth, or agar dilution methods.

Because *S. aureus* is a common cause of human infection, the emergence of VRSA is of great concern for the treatment of MRSA infections. There is therefore the need for continuous research on phenotypic identification and genetic detection of VRSA. This study was conducted to detect the biochemical and genetic characteristics of vancomycin resistance in *S. aureus* as a follow-up to a previous study \[[@ref35]\] which reported phenotypic isolation of high level vancomycin-resistant *S. aureus* in Osogbo, Nigeria.

Materials and Methods {#sec1-2}
=====================

**Study Design.** The research is descriptive cross sectional, conducted over a 6-month period (July 2015 to January 2016) on patients who were either hospitalized or on outpatient treatment for infections at the Ladoke Akintola University of Technology (LAUTECH) Teaching Hospital, Osogbo, Nigeria. A total of 73 consecutive patients who gave informed consent were enrolled over the study period. Appropriate microbiological samples were collected from the patients and processed at the Bacteriology Laboratory of the hospital, while molecular characterization was done at the Molecular Microbiology Laboratory of the College of Health Sciences, LAUTECH, Osogbo. Relevant clinical data of each patient were collected into a designed proforma.

**Isolation and Identification of *S. aureus.*** *S. aureus* was identified by characteristic growth on Mannitol Salt Agar (MSA), positive catalase, tube coagulase, and deoxyribonuclease (DNAse) tests \[[@ref37]\]. The isolates were confirmed by amplification of SA *nuc* gene on PCR.

**Antibiotic Susceptibility Test by Disk Diffusion.** The susceptibility of each *S. aureus* isolate and control strain (*S. aureus* ATCC 29213) to single antibiotic disk; amoxicillin, erythromycin, tetracycline, gentamicin, cotrimoxazole, chloramphenicol, fusidic, and novobiocin (Oxoid, UK) was performed in triplicate using the method of Bauer *et al.* \[[@ref38]\]. The diameters of zone of inhibition that determine *S. aureus* susceptibility to each antibiotic were as follows: amoxicillin, ≥20 mm; erythromycin, ≥23 mm; tetracycline, ≥19 mm; gentamicin, ≥15 mm; cotrimoxazole, ≥16 mm; chloramphenicol, ≥18 mm; fusidic, ≥24 mm; and novobiocin, ≥16 mm \[[@ref39]\].

**Vancomycin E-test Method.** The Minimum inhibitory concentration (MIC) of each *S. aureus* isolate and control strains (*Enterococcus faecalis* ATCC 29212 and *S. aureus* ATCC 29213) to vancomycin was determined in triplicate using vancomycin E-test (Epsilom test) strip (Solna, Sweden). The MIC for each isolate was compared with the interpretive standard of the Clinical and Laboratory Standards Institute (CLSI) to determine sensitivity or resistance. Isolate with vancomycin MIC of ≤2 μg/ml was categorized as vancomycin-susceptible *S. aureus* (VSSA), MIC 4--8 μg/ml as VISA and MIC of ≥16 μg/ml as VRSA \[[@ref39]\]. The vancomycin MIC of *S. aureus* ATCC 29213 (negative control) was \<2 μg/ml while that of *E. faecalis* ATCC 29212 (positive control strain) was 4 μg/ml.

**Detection of *van*, *nuc*, and *mecA* genes by PCR.** *S. aureus* vancomycin resistance genes (*vanA* and *vanB*), nuclease gene (*nuc*), and methicillin resistance gene (*mecA*) were detected by conventional singleplex polymerase chain reaction (PCR) assay.

***1. DNA Extraction.*** DNA was extracted by the modification of simple crude extraction method previously described \[[@ref31]\]. Briefly, 4 to 5 colonies of bacteria cells were scooped into Eppendorf tubes containing 500 µL of Tris Borate Ethylene diamine tetra acetic acid (TBE) buffer. This was boiled at 100 °C for 10 min after which it was cooled rapidly at --20 °C for 30 min. Three microliters of proteinase K was added to the lysed cells, and the mixture was incubated for 15--20 min at 55--60 °C. The enzyme was denatured at 100 °C for 10 min. The mixture was then centrifuged at 15,000 × *g* for 30 s. The supernatant containing the DNA was stored at --20 °C until use.

***2. Amplification by PCR.** S. aureus nuc* gene was amplified with SANuc F primer (-gcgattgatggtgatacggtt-) and SANuc R primer (-agccaagccttgacgaactaaagc-). The *vanA* and *vanB* genes were amplified with primers VanA F (-gggaaaacgacaattgc-) and VanA R (-gtacaatgccgtta-) and primers VanB F (-tctgtttgaattgtctggtat-) and VanB R (-gacctcgtttagaacgatg-). The *mecA* gene was amplified with primer MecA F (-gtagaaatgactgaacgtccgataa-) and MecA R (-ccaattccacattgtttcggtctaa-).

The reaction was set up in a PCR vial, after adding the master mix, the forward and reverse primers, and the extracted DNA. A 25 µL of master mix contained 4 µL of 10× buffer, 0.5 µL MgCl~2~, 3 µL dNTPs, and 0.2 µL Taq polymerase. The PCR vial was then placed in the PCR machine (Prime Therma cycler, UK). For amplification of *nuc* gene, initial denaturation occurred at 94 °C for 2 min, followed by 35 cycles of denaturation at 94 °C for 30 s, annealing at 58 °C for 30 s and elongation at 72 °C for 30 s, and a final extension at 72 °C for 7 min \[[@ref40]\]. For amplification of *mecA* gene, initial denaturation was at 94 °C for 4 min, followed by 30 cycles of denaturation at 94 °C for 45 s, annealing at 50 °C for 30 sec and elongation at 72 °C for 1 min, and a final extension at 72 °C for 3 min \[[@ref41]\]. For amplification of *vanA* gene, initial denaturation occurred at 94 °C for 2 min, followed by 30 cycles of denaturation at 94 °C for 1 min, annealing at 54 °C for 1 min, elongation at 72 °C for 1 min, and a final extension at 72 °C for 10 min \[[@ref42]\]. For the amplification of *vanB* gene, initial denaturation occurred at 94 °C for 5 min, followed by 30 cycles of denaturation at 94 °C for 25 s, annealing at 52 °C for 40 s, elongation at 72 °C for 1 min, and final extension at 72 °C for 6 min \[[@ref43]\].

***3. Gel Electrophoresis.*** At the completion of the amplification of each gene, the PCR amplicons were resolved on agarose gel electrophoresis. Agarose gel (1%), into which 0.5 µL ethidium bromide had been added, was first prepared. The gel plates were then placed inside electrophoresis tank (Weal Tek Corp., Taiwan) which contained 1× TBE solution. A 5 µL of amplicon was mixed with 5 µL Orange G (loading buffer) and loaded to the well of the agarose gel. The power supply was adjusted to 100 volts for 25 min. For each run, a 100 base-pair molecular weight DNA standard (New England Biolabs "NEB") was used to determine the size of each PCR amplicon. The DNA bands were then visualized with a short wave ultraviolet trans-illuminator and photographed using gene gel bio-imaging system (UVP Imaging System, Upland, CA, USA) and products analyzed.

***4. Results and Interpretation.*** Expected band for *S. aureus nuc* gene is approximately 276 bp, *vanA* gene 732 bp, *vanB* gene 807 bp, and *mecA* gene 310 bp.

***Data Entry and Statistical Analysis.*** All data (clinical and laboratory) were entered into Window 7 laptop computer with GraphPad statistical software. Frequency tables were generated, and relationship between variables tested with χ^[@ref2]^ with significant value set at*p \<* 0.05.

**Ethics Statement.** Informed consent was obtained from each patient-participant. Approval of the hospital Ethics and Research Committee (ERC) was obtained prior to conduct of the study.

Results {#sec1-3}
=======

Non-duplicate *S. aureus* was isolated from 73 consecutive patients with different infective conditions as shown in [Table 1](#table001){ref-type="table"}. Non-surgical wound infections accounted for the largest percentage (30.1%); followed by otitis media (12.3%); pelvic inflammatory disease (10.9%); bacterial conjunctivitis (8.2%); surgical site infection, osteomyelitis, urinary tract infection, and abscess (5.5%); septic arthritis (4.2%); and others (9.6%), while necrotizing fasciitis and blood stream infection constituted the lowest percentage (1.4%).

[Table 2](#table002){ref-type="table"} shows the distribution of *S. aureus* isolates by methicillin and vancomycin susceptibility; 61 (83.6%) of the isolates were VSSA, 11 (15.1%) were VISA, and 1 (1.4%) was VRSA. A total of 68 (93.2%) isolates were methicillin-susceptible *S. aureus (*MSSA; *mecA* negative), while 5 (6.8%) were MRSA (*mecA* positive). The prevalence of MRSA in the study was 6.8%.

[Table 3](#table003){ref-type="table"} shows the antibiotic susceptibility of VSSA isolates assessed by the disk diffusion method to selected antibiotics. Most of the VSSA isolates were resistant to commonly used antibiotics in the environment but were mostly sensitive to novobiocin (78.7%) and gentamicin (73.8%).

[Table 4](#table004){ref-type="table"} displays antibiotic susceptibility of VISA isolates applying the disk diffusion method to selected antibiotics. Almost all the VISA isolates were resistant to the antibiotics tested. Only few, however, were sensitive to gentamicin (36.4%), tetracycline (9.1%), and cotrimoxazole (9.1%). The only VRSA isolate (with vancomycin MIC = 16 μg/ml) was resistant to all antibiotic disks tested in the study.

[Table 5](#table005){ref-type="table"} shows the comparison of resistant profile of VSSA and VISA isolates to selected antibiotics. Both VSSA and VISA isolates showed high *in vitro* resistance to multiple antibiotics tested with the VISA isolates being more significantly resistant to gentamicin (*p* = 0.0302), chloramphenicol (*p* = 0.0049), fusidic acid (*p* = 0.0056), and novobiocin (*p* \< 0.0001). The only vancomycin-resistant isolate was resistant to all antibiotics tested.

All *S. aureus* isolates, including the 11 VISA and 1 VRSA strains, were positive for *nuc* gene ([Figure 1](#fig001){ref-type="fig"}). Five isolates were *mecA* gene positive which confirmed them to be MRSA ([Figure 2](#fig002){ref-type="fig"}) and were either VISA or VRSA. All the VISA and VRSA isolates were *vanA* and *vanB* gene negative.

Discussion {#sec1-4}
==========

Since VISA was first reported in the 1997 \[[@ref14], [@ref15]\] and VRSA in 2002 \[[@ref16]\], the threat of vancomycin resistance in *S. aurleus* has been of great concern and a threat to public health. This has made the study of VISA and VRSA a topic of intensive research, although there have been limited reports of clinical infections caused by VRSA worldwide \[[@ref12], [@ref19], [@ref21], [@ref23]\], while infections caused by VISA continued to be reported from different parts of the world \[[@ref44]\]. As there have also been previous reports of phenotypic resistance of MRSA to vancomycin in our environment \[[@ref32]\], the present study was designed to investigate the molecular basis of this resistance.

This study detected VRSA in 1 (1.4%) out of 73 *S. aureus* isolates, which was isolated from a surgical site infection (SSI) and resistant to all antibiotics tested in the study. The strain displayed a vancomycin MIC value of 16 μg/ml and carried a *mecA* gene but did not contain *vanA* or *vanB* gene. In our previous study \[[@ref35]\], we isolated VRSA strains (12.2%, 6 of 49 *S. aureus* isolates) with vancomycin MIC of \>256 μg/ml from patients with wound infection and chronic osteomyelitis, who had been on prolonged hospitalization. Similarly, there was a 5.3% VRSA prevalence rate reported among clinical patients in a hospital in Eastern part of Nigeria \[[@ref36]\] and 5.4% positivity rate in fresh and fermented milk obtained from animals in Northern Nigeria \[[@ref48]\]. The importance of all these findings is that VRSA isolates are increasingly emerging in several parts of the world including Nigeria. There remains a public health threat from these emerging *S. aureus* strains that can no longer be ignored.

The molecular basis of all VRSA isolates is yet to be clearly elucidated, but it has been shown in some that phenotypic resistance is conferred by induction of the *vanA* operon found on transposon *Tn1546* and carried by Inc18-like plasmid from coinfecting vancomycin-resistant enterococci \[[@ref12]\]. The transfer of this plasmid requires the presence of a pSK41-like plasmid in recipient *S. aureus* \[[@ref49]\]. In our study, however, the only VRSA isolate neither contains *vanA* nor *vanB* gene that has been described to be present in all confirmed VRSA isolates reported so far \[[@ref12]\]. It is possible that other van operons (*vanC, vanD, vanE, vanG*, or *vanL*) found in enterococci may also be transferrable to *S. aureus* subsequently conferring vancomycin resistance to the *S. aureus* recipient strain. Although there was no coinfection of enterococci in the patient from whom our VRSA isolate was recovered from, we believe that the range of *van* operons routinely tested in *S. aureus* exhibiting resistance phenotype to vancomycin should be expanded to other *van* operons aside *vanA* and *vanB*.

Eleven (15.1%) of the *S. aureus* isolates in this study were VISA (vancomycin MIC of 4--8 μg/ml) involved in different types of infection. The mechanism of resistance in VISA is yet to be fully explained although sequestering of glycopeptide (vancomycin and teicoplanin) in the periphery of the cell due to thickening of the wall from accumulation of peptidoglycan precursor, acyl-D-alanyl-D-alanine dipeptide, has been reported to reduce penetration of the drug to its target site \[[@ref9]\]. The genetic basis of this remains largely unexplained as no gene or operon has been linked with VISA, although frequent exposure of patients to high dosages of different antibiotics including vancomycin, which may cause chromosomal mutations, has been implicated. Our 11 VISA isolates neither contain *vanA* nor *vanB* gene, although four of them carried the *mecA* gene. This result is in line with other studies from Nigeria \[[@ref33], [@ref35]\] and Iran \[[@ref21], [@ref47]\].

We observed in this study that the prevalence of MRSA was 6.8%, all of which were VISA and VRSA strains and resistant to most of the antibiotics used in the study. The only VRSA strain was resistant to all the antibiotics tested including amoxicillin, erythromycin, tetracycline, gentamicin, cotrimoxazole, chloramphenicol, fusidic acid, and novobiocin. This finding is supported by a previous report \[[@ref50]\] in which VRSA and heterogeneous vancomycin-resistant *S. aureus* (hVRSA) isolates were resistant to 21 different antibiotics including methicillin, tetracycline, gentamicin, and erythromycin. The efficacy of vancomycin in treatment of severe MRSA infections is gradually being eroded by the emergence of VISA and VRSA strains. Moreover, these strains have been found to be resistant to multiple antibiotics thereby making antibiotic selection more difficult in this era of decreasing pipeline of new antibiotic discovery. Although the occurrence of VRSA strain is thought to be geographically restricted due to several biological constraints that limit the spread of the *van* plasmids between strains \[[@ref12]\], the potential for spread should not be underestimated especially with discovery that *S. aureus* harboring the pSK41-like plasmid readily accept *van* plasmid \[[@ref49]\].

Conclusions {#sec1-5}
===========

In conclusion, this study confirms the occurrence of multiple antibiotic resistant VISA and emergence of VRSA isolates involved in clinical infections in Nigeria, whereas the genetic basis remains to be elucidated, however. There is further need to curtail further emergence and possible spread of these strains by reducing the glycopeptide pressure through appropriate prescribing and initiating infection control measures.
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![Gel electrophoresis of PCR amplification of *nuc* gene. L = 100 bp ladder 1, 2, 3, 4, 5, 7, 8, 9, 10, 11 = *nuc* positive isolates; 6 = *nuc* positive control; not labeled = *nuc* negative control (PCR water)](eujmi-08-025-g001){#fig001}

![Gel electrophoresis of PCR amplification of *mecA* gene. L = 100 bp ladder; 1, 2, 3, 4 = *mecA* positive isolates; 5 = *mecA* negative isolate; NC = *mecA* negative control; PC = *mecA* negative control (PCR water)](eujmi-08-025-g002){#fig002}

###### 

Distribution of Staphylococcus aureus isolates by clinical infection types

  Clinical infections             Staphylococcus aureus isolates                                               
  ------------------------------- -------------------------------- --------- ----------- ----------- --------- -----------
  Non-surgical wound infections   20                               2         18          4           0         22 (30.1)
  Surgical site infection         3                                1         3           0           1         4 (5.5)
  Septic arthritis                3                                0         3           0           0         3 (4.2)
  Osteomyelitis                   4                                0         4           0           0         4 (5.5)
  Otitis media                    8                                1         7           2           0         9 (12.3)
  Urinary tract infection         3                                1         1           3           0         4 (5.5)
  Bacteria conjunctivitis         6                                0         6           0           0         6 (8.2)
  Necrotizing fasciitis           1                                0         1           0           0         1 (1.4)
  Blood stream infection          1                                0         1           0           0         1 (1.4)
  Abscess                         4                                0         4           0           0         4 (5.5)
  Pelvic inflammatory disease     8                                0         6           2           0         8 (10.9)
  Others (non-specified)          7                                0         7           0           0         7 (9.6)
  Total (%)                       68 (93.2)                        5 (6.8)   61 (83.6)   11 (15.1)   1 (1.4)   73(100)

MSSA, methicillin-sensitive *Staphylococcus aureus;* MRSA, methicillin-resistant *Staphylococcus aureus;* VSSA, vancomycin-sensitive *Staphylococcus aureus;* VISA, vancomycin intermediate-resistant *Staphylococcus aureus;* VRSA, vancomycin-resistant *Staphylococcus* aureus.

###### 

Distribution of *Staphylococcus aureus* isolates by methicillin and vancomycin susceptibility

  *Staphylococcus aureus* isolates   Vancomycin susceptibility (E-test) MIC   Total (%)             
  ---------------------------------- ---------------------------------------- ----------- --------- -----------
  MSSA                               61                                       7           0         68 (93.2)
  (*mecA* gene negative)                                                                            
  MRSA                               0                                        4           1         5 (6.8)
  (*mecA* gene positive)                                                                            
  Total (%)                          61 (83.6)                                11 (15.1)   1 (1.4)   73(100)

MSSA, methicillin-sensitive *Staphylococcus aureus;* MRSA, methicillin-resistant *Staphylococcus aureus;* VSSA, vancomycin-sensitive

*Staphylococcus aureus;* VISA, vancomycin intermediate-resistant

*Staphylococcus aureus;* VRSA, vancomycin-resistant *Staphylococcus aureus.*

###### 

Antibiotic susceptibility of VSSA isolates by disk diffusion method to selected antibiotics

  Antibiotic disk   Susceptibility profile of VSSA isolates (*n* = 61)   
  ----------------- ---------------------------------------------------- -----------
  Amoxicillin       8 (13.1)                                             53 (86.9)
  Erythromycin      4 (6.6)                                              57 (93.4)
  Tetracycline      20 (32.8)                                            41 (67.2)
  Gentamicin        45 (73.8)                                            16 (26.2)
  Cotrimoxazole     18 (29.5)                                            43 (70.5)
  Chloramphenicol   28 (45.9)                                            33 (54.1)
  Fusidic acid      26 (42.6)                                            35 (57.4)
  Novobiocin        48 (78.7)                                            13 (21.3)

###### 

Antibiotic susceptibility of VISA isolates by disk diffusion method to selected antibiotics

  Antibiotic disk   Susceptibility profile of VISA isolates (*n* = 11)   
  ----------------- ---------------------------------------------------- -----------
  Amoxicillin       0                                                    11(100)
  Erythromycin      0                                                    11(100)
  Tetracycline      1 (9.1)                                              10 (90.9)
  Gentamicin        4 (36.4)                                             7 (63.6)
  Cotrimoxazole     1 (9.1)                                              10 (90.9)
  Chloramphenicol   0                                                    11(100)
  Fusidic acid      0                                                    11(100)
  Novobiocin        0                                                    11(100)

###### 

Comparison of resistant profile of VSSA and VISA isolates to selected antibiotics

  Antibiotic disk   Resistance of VSSA (%) (*n* = 61)   Resistance of VISA (%) (*n* = 11)   *p* Value
  ----------------- ----------------------------------- ----------------------------------- ---------------------------------------------
  Amoxicillin       53 (86.9)                           11(100)                             0.3439
  Erythromycin      57 (93.4)                           11(100)                             1.000
  Tetracycline      41 (67.2)                           10 (90.9)                           0.1579
  Gentamicin        16 (26.2)                           7 (63.6)                            0.0302[\*](#tfn001){ref-type="table-fn"}
  Cotrimoxazole     43 (70.5)                           10 (90.9)                           0.2674
  Chloramphenicol   33 (54.1)                           11(100)                             0.0049[\*](#tfn001){ref-type="table-fn"}
  Fusidic acid      35 (57.4)                           11(100)                             0.0056[\*](#tfn001){ref-type="table-fn"}
  Novobiocin        13 (21.3)                           11(100)                             \< 0.0001[\*](#tfn001){ref-type="table-fn"}

\*Significant difference.
